Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide Tablet
finanznachrichten.de     May 17, 2008            

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older. “Late this... [read full story]                    


View all news articles about*:
Pharmaceuticals Salix
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

                   

InPlay: Home Depot beats by $0.10, beats on revs (Briefing.com)

yahoo.com     Aug 19, 2008          

6:05AM GigaMedia appoints Quincy Tang as Chief Financial Officer 12.63 : 6:03AM Home Depot beats by $0.10, beats on revs 26.96 : Reports Q2 (Jul) earnings of $0.71 per share, $0.10 better than the First Call consensus of $0.61;...                    

comments

Salix Pharma offers $55 million in senior notes

ibtimes.com     Aug 19, 2008   16 related          

Salix Pharmaceuticals Ltd., a drug developer, said late Monday it priced an offering of $55 million in convertible senior notes due 2028. Salix, which focuses on gastrointestinal diseases, plans to use proceeds from the sale of...                    

comments

                   

InPlay: LDK Solar awards $220 mln contract to Applied Materials for precision wafering systems to...

yahoo.com     Aug 19, 2008   6 related          

3:28AM LDK Solar awards $220 mln contract to Applied Materials for precision wafering systems to support production expansion 18.79 : LDK Solar (LDK) awards a $220 mln contract to co to provide precision wafering systems to...                    

comments

Salix trying to raise $50 million to expand

newsobserver.com     Aug 19, 2008   1 related          

Sabine Vollmer, Staff WriterComment on this story Salix Pharmaceuticals announced plans Monday to raise $50 million to expand its product lineup, boost revenue and ease the increasing pressure from generic competitors. The...                    

comments